Ayanna S Bryan

US Patent:

20200229744, Jul 23, 2020

Filed:

Jan 21, 2020

Appl. No.:

16/748336

Inventors:

- New York NY, US
Ayanna Bryan - Bloomfield NJ, US
Martin Smithmyer - New York NJ, US

Assignee:

AMERICORD REGISTRY LLC - New York NY

International Classification:

A61B 5/15

Abstract:

A device and method for the collection of blood from an umbilical cord. Unlike other devices traditionally used which make use of a needle for insertion through the cord tissue and into the umbilical vein, the present device includes a long probe to be inserted into the umbilical vein after the umbilical cord is cut. The device additionally includes a fastening component to be tied around the umbilical cord under the position of the head of the device once inserted to fasten it in place. The device has a wide aperture for faster flow of the blood at a constantly tapered angle to reduce shear forces that may damage cells. Additionally, the head of the device is angled for easy insertion into the umbilical vein and is ribbed to resist falling out of the vein.

US Patent:

20200230175, Jul 23, 2020

Filed:

Jan 21, 2020

Appl. No.:

16/748390

Inventors:

- New York NY, US
Ayanna Bryan - Bloomfield NJ, US
Martin Smithmyer - New York NJ, US

Assignee:

AMERICORD REGISTRY LLC - New York NY

International Classification:

A61K 35/28
A01N 1/02

Abstract:

Methods for the ex vivo use of NAD to remove T cells that can potentially cause graft-verus-host disease (GvHD) from hematopoietic stem cell sources. Hematopoietic stem cell sources include bone marrow, cord blood, and peripheral blood (including mobilized peripheral blood). The present invention is a method including steps for using the hematopoietic stem cell sources treated with NAD for hematopoietic stem cell transplants (HSCTs). HSCTs are used as the standard-of-care in many diseases including several types of cancer and several genetic disorders. The majority of these transplants are allogeneic, in which the stem cell source comes from a donor who is a different individual than the intended recipient. Allogeneic HSCTs carry a risk of causing GvHD, in which donor T cells attack the recipient.